Literature DB >> 16000561

Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.

Norihiro Sato1, Hiroyuki Matsubayashi, Tadayoshi Abe, Noriyoshi Fukushima, Michael Goggins.   

Abstract

PURPOSE: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is an increasingly identified precursor to infiltrating ductal adenocarcinoma. Although our knowledge of the clinical and pathologic features of IPMNs is increasing, the molecular mechanisms underlying these neoplasms remain poorly understood. EXPERIMENTAL DESIGNS: To provide further insight into the molecular pathobiology of IPMNs, global expression profiling was done to determine genes that are inactivated/down-regulated in IPMNs using oligonucleotide microarrays (Affymetrix).
RESULTS: In total, 300 unique transcripts (217 known genes) were identified as highly underexpressed in 12 IPMNs (<10-fold lower and P < 0.05) compared with five normal pancreatic ductal epithelium samples obtained by laser capture microdissection. The differential expression of a selection of genes was confirmed using reverse-transcription PCR. One of the genes underexpressed at both the transcriptional and protein level in a significant proportion of IPMNs was the cyclin-dependent kinase inhibitor, CDKN1C/p57KIP2. CDKN1C expression was also decreased in many pancreatic cancer cell lines and was restored following treatment with a DNA methylation inhibitor (5-aza-2'-deoxycitidine) or, more potently, with a histone deacetylase inhibitor (trichostatin A). Partial methylation of the CDKN1C promoter CpG island was found in most, but not all, pancreatic cancer cell lines with reduced CDKN1C expression, and was also detectable in IPMNs. Furthermore, a subset of pancreatic cancers showed complete hypomethylation of LIT1, an imprinting control region important for the regulation of CDKN1C expression. Complete hypomethylation in these cancers was the result of deletion of the methylated LIT1 allele at 11p15.5 rather than loss of imprinting.
CONCLUSIONS: These findings suggest that CDKN1C is commonly down-regulated in pancreatic ductal neoplasms through a combination of promoter hypermethylation, histone deacetylation, and loss of the maternal allele expressing CDKN1C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000561     DOI: 10.1158/1078-0432.CCR-04-2471

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  Insights into the role of DNA methylation in disease through the use of mouse models.

Authors:  Melissa Conerly; William M Grady
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

3.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2010-02-01       Impact factor: 4.742

4.  Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Jing-Jing Zhang; Yi Zhu; Yan Zhu; Jun-Li Wu; Wen-Biao Liang; Rong Zhu; Ze-Kuan Xu; Qing Du; Yi Miao
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

5.  Molecular determinants of retinoic acid sensitivity in pancreatic cancer.

Authors:  Sonal Gupta; Dipankar Pramanik; Radha Mukherjee; Nathaniel R Campbell; Sathyanarayanan Elumalai; Roeland F de Wilde; Seung-Mo Hong; Michael G Goggins; Ana De Jesus-Acosta; Daniel Laheru; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

Review 6.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 7.  Current evidence for histone deacetylase inhibitors in pancreatic cancer.

Authors:  Ioannis Koutsounas; Constantinos Giaginis; Efstratios Patsouris; Stamatios Theocharis
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

8.  Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma.

Authors:  Audrey Vincent; Noriyuki Omura; Seung-Mo Hong; Andrew Jaffe; James Eshleman; Michael Goggins
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

9.  TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57KIP2 repression.

Authors:  Xiaomeng Li; Xianhui Ruan; Peitao Zhang; Yang Yu; Ming Gao; Shukai Yuan; Zewei Zhao; Jie Yang; Li Zhao
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

10.  DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease.

Authors:  Mansour A Parsi; Ang Li; Chung-Pin Li; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-05       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.